MARVELD1 Antibody | 5499

MARVELD1 Antibody | 5499 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: MARVELD1 antibody was raised against a 16 amino acid synthetic peptide from near the amino terminus of human MARVELD1.
The immunogen is located within the first 50 amino acids of MARVELD1.

Research Area: Cancer

Tested Application: E, WB

Application: MARVELD1 antibody can be used for detection of MARVELD1 by Western blot at 1 - 2 μg/mL.
Antibody validated: Western Blot in mouse samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1401 - Mouse Heart Tissue Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: MARVELD1 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: MARVELD1 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: MARVELD1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: MARVELD1 Antibody: MRVLDC1, MARVEL domain-containing protein 1

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: MARVELD1 Antibody: MARVELD1, (MARVEL domain-containing 1) , is one of the MARVEL (MAL and related proteins for vesicle trafficking and membrane link) domain-containing proteins. It is a nuclear-localized protein that is widely expressed in normal human tissues. While it has been reported to be overexpressed in colon cancer, MARVELD1 protein levels are generally lower in several primary tumors including ovary, breast, kidney, bladder and liver. This lower level of MARVELD1 expression in tumors is thought to be due to a higher methylation status of the MARVELD1 promoter as treatment of MDA-MB-361 with 5-aza-2'-deoxycytidine restores MARVELD1 expression, suggesting that loss of MARVELD1 expression may contribute to tumorgenicity.